
Over 14,000 attendees from around the world attended the 71st AAN Annual Meeting in Philadelphia. With 3,000+ presented abstracts, every aspect of brain research has its place at the conference, meaning every neurologist can find their topic of interest.
Progress in common disorders such as dementia, epilepsy, migraine, and multiple sclerosis and advances in oligonucleotide approaches to rare diseases
While research successfully continues in major fields of dementia, epilepsy, migraine, and multiple sclerosis, this yearās AAN was one of emerging science in more rare disorders. Very positive results were reported for three phase 3 trials using three different monoclonal antibodies in NMOSD, which might result in the first approved therapies. Progress has also been made regarding treatment options in rare neuromuscular disorders, such as myasthenia gravis, Charcot-Marie-Tooth, and spinal muscular atrophy. Clearly the search for effective treatments in all fields of neurology needs to continue. The same holds for improved diagnosis and disease management, with an ever-increasing role for digital technologies.
This report includes summaries of these presentations and more. We hope to provide an interesting read for those who were unable to attend, or would like to recap their experience at a busy conference.
Best regards,
Hans-Peter Hartung
Biography
Prof. Hartung has been Chair of the Department of Neurology at Heinrich-Heine-University in DĆ¼sseldorf since 2001. He is also Director of the Center of Neuropsychiatry and the Department of Conservative Medicine at University Hospital DĆ¼sseldorf.
He studied medicine at the Universities of DĆ¼sseldorf, Glasgow, Oxford, and London. After graduation he served an immunology fellowship at the University of Mainz.
Prof. Hartungās clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies. He has been involved as steering committee member in multiple clinical trials of new drugs for the treatment of multiple sclerosis, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy.
Prof. Hartung is a former President of ECTRIMS.
Disclosures:Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, and Teva, with approval by the Rector of Hein-rich-Heine-University.
Posted on
Previous Article
« Possibly lifesaving therapy in refractory PML Next Article
Promising news for gene therapy for sickle cell disease »
« Possibly lifesaving therapy in refractory PML Next Article
Promising news for gene therapy for sickle cell disease »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinsonās Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles
July 30, 2019
T-type-calcium channel modulator in essential tremor

July 30, 2019
Biotin, ocrelizumab, and ibudilast in progressive MS
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com